CD33 and acute myeloid leukemia: CAR-T approaches to target AML-associated antigens (CD33 and CD123) have been explored in preclinical models, but it appeared that yet to be defined more tumor cell-selective epitopes might be necessary to reach the efficacy observed in B-ALL (174).